A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERα-positive breast cancer cells

Yanshu Li(China Medical University), Feng Li(Guangdong Ocean University), Nanxi Geng(China Medical University), Furong Liu(Sun Yat-sen University), Chunyu Wang(King University), Yuee Teng(First Hospital of China Medical University), Yue Zhao(Sun Yat-sen University), Liu Cao(China Medical University), Hongyan Zhang(Tianjin University), Feng Jin(Hebei University), Jiabin Li(China Medical University), Yang Li(Nantong University), Yan Li(Chongqing University), Rui Xue(Shihezi University), Rakesh Kumar(The University of Texas MD Anderson Cancer Center), Yunling Gao(China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Zhenguo Cheng(China Medical University)
Oncogene
September 3, 2018
10.1038/s41388-018-0456-0
Cited by 48

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
|Gut|2020|578
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417